

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725

Provisional Stakeholder List

Consultees Commentators (no right to submit or	
Consultees	Commentators (no right to submit or
0	appeal)
Company	General
AstraZeneca (durvalumab,	All Wales Therapeutics and Toxicology
tremelimumab)	Centre
	Allied Health Professionals Federation
Patient/carer groups	Board of Community Health Councils in
Addenbrookes Liver Transplant	Wales
Association	British National Formulary
Black Health Agency for Equality	Care Quality Commission
British Liver Trust	 Department of Health, Social Services
Cancer Black Care	and Public Safety for Northern Ireland
Cancer Equality	Healthcare Improvement Scotland
Cancer 52	 Medicines and Healthcare products
GUTS UK	Regulatory Agency
Haemochromatosis UK	National Association of Primary Care
Helen Rollason Cancer Charity	National Pharmacy Association
Hepatitis C Trust	NHS Confederation
Independent Cancer Patients' Voice	Scottish Medicines Consortium
Liver4Life	Welsh Government
Macmillan Cancer Support	Welsh Health Specialised Services
Maggie's Centres	Committee
Marie Curie	
Pelican Cancer Foundation	Possible comparator companies
South Asian Health Foundation	Bayer (sorafenib)
Specialised Healthcare Alliance	Boston Scientific (TheraSphere)
Tenovus Cancer Care	Celltrion Healthcare (bevacizumab)
	Dr. Reddy's Laboratories
Healthcare professional groups	(bevacizumab)
Association of Anaesthetists of Great	Eisai (lenvatinib)
Britain & Ireland	Organon Pharma (bevacizumab)
Association of Cancer Physicians	Pfizer (bevacizumab)
Association of Surgeons of Great	Roche (atezolizumab, bevacizumab)
Britain & Ireland	Sandoz (sorafenib)
British Association of the Study of the	Sirtex (SIR-Spheres)
Liver	Terumo Europe (QuerumSphere)
British Geriatrics Society	Thornton and Ross (bevacizumab,
British Institute of Radiologists	sorafenib)

Provisional stakeholder list for the evaluation of durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725 Issue date: April 2024



Consultees	Commentators (no right to submit or appeal)
 British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Gastroenterology Cancer Research UK Hepatitis Nurse Specialist Forum Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiologists UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care 	 Zentiva (bevacizumab, sorafenib) Relevant research groups Cochrane Hepato-biliary Group Cochrane Infectious Diseases Group Cochrane UK Foundation for Liver Research Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency
Department of Health and Social CareNHS England	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma ID2725 Issue date: April 2024



Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.